Moonlake Immunotherapeutics (MLTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -167,303 | -96,611 | -40,559 | -121,244 | -74,849 |
| Depreciation Amortization | 1,865 | 1,120 | 378 | 1,385 | 1,021 |
| Accounts receivable | -1,178 | -566 | -146 | -1,786 | -1,350 |
| Accounts payable and accrued liabilities | 16,290 | 8,087 | 3,013 | 7,155 | 8,873 |
| Other Working Capital | 19,872 | -1,558 | -369 | -3,784 | 118 |
| Other Operating Activity | -6,759 | -3,142 | -457 | 1,687 | -1,927 |
| Operating Cash Flow | $-137,213 | $-92,670 | $-38,140 | $-116,587 | $-68,114 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 232,938 | 144,535 | 56,281 | -205,076 | -57,921 |
| PPE Investments | -35 | -35 | -35 | -520 | -344 |
| Investing Cash Flow | $232,903 | $144,500 | $56,246 | $-205,595 | $-58,265 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 73,022 | 73,022 | 73,022 | N/A | N/A |
| Common Stock Issued | N/A | N/A | N/A | 52,540 | 52,540 |
| Other Financing Activity | 580 | 100 | 100 | -1,229 | -1,379 |
| Financing Cash Flow | $73,602 | $73,122 | $73,122 | $51,312 | $51,161 |
| Exchange Rate Effect | 1,018 | 1,303 | -88 | 128 | -296 |
| Beginning Cash Position | 180,426 | 180,426 | 180,426 | 451,169 | 451,169 |
| End Cash Position | 350,736 | 306,681 | 271,566 | 180,427 | 375,655 |
| Net Cash Flow | $170,310 | $126,255 | $91,140 | $-270,743 | $-75,514 |
| Free Cash Flow | |||||
| Operating Cash Flow | -137,213 | -92,670 | -38,140 | -116,587 | -68,114 |
| Capital Expenditure | -35 | -35 | -35 | -520 | -344 |
| Free Cash Flow | -137,248 | -92,705 | -38,175 | -117,107 | -68,458 |